EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A 10 Year Long‐Lived Cellular and Humoral MERS‐CoV Immunity Cross‐Recognizing the Wild‐Type and Variants of SARS‐CoV‐2: A Potential One‐Way MERS‐CoV Cross‐Protection Toward a Pan‐Coronavirus Vaccine

Bandar Alosaimi iD, Maaweya Awadalla iD, Wael Alturaiki, Zhao Chen, Zhaoyong Zhang, Airu Zhu, Fatimah Rebh, Abeer N Alshukairi, Jincun Zhao, Haitham S Alkadi

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Bandar Alosaimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, SARS-CoV-2, Immunity, Humoral, Cross Protection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by the Research Center at King Fahad Medical City (Grant No. IRF 019-058)., King Fahad Medical City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MERS is a respiratory disease caused by MERS‐CoV. Multiple outbreaks have been reported, and the virus co‐circulates with SARS‐CoV‐2. The long‐term (> 6 years) cellular and humoral immune responses to MERS‐CoV and their potential cross‐reactivity to SARS‐CoV‐2 and its variants are unknown. We comprehensively investigated long‐lasting MERS‐CoV‐specific cellular and humoral immunity, and its cross‐reactivity against SARS‐CoV‐2 and its variants, in individuals recovered from MERS‐CoV infection 1–10 years prior. Two cohorts of MERS‐CoV survivors (31 unvaccinated, 38 COVID‐19 vaccinated) were assessed for MERS‐CoV IgG, memory CD4 + /CD8 + T cells, and neutralizing antibodies against MERS‐CoV and SARS‐CoV‐2 variants. MERS‐CoV IgG levels and T cell responses were higher in the 1–5 vs 6–10 year postinfection groups. Vaccinated MERS‐CoV survivors had significantly elevated MERS‐CoV IgG and neutralization compared to unvaccinated. Both groups demonstrated cross‐reactive neutralization of SARS‐CoV‐2 variants. MERS‐CoV survivors vaccinated against SARS‐CoV‐2 had higher anti‐MERS IgG, cellular immunity, and neutralization than unvaccinated survivors. MERS‐CoV immune responses can persist for a decade. COVID‐19 vaccination boosted humoral and cellular immunity in MERS‐CoV survivors, suggesting the benefits of vaccination for this population. These findings have implications for pan‐coronavirus vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Middle East Respiratory Syndrome CoronavirusSARS-CoV-2Immunity, HumoralCross ProtectionImmunity, CellularViral VaccinesHumansAntibodies, ViralAntibodies, NeutralizingImmunoglobulin GMiddle AgedCross ReactionsMaleFemaleAdultCOVID-19AgedCOVID-19 VaccinesCD8-Positive T-LymphocytesCD4-Positive T-LymphocytesVaccination

Stichwörter der Autor:innen

BA.5 variantDelta variantMERS‐CoVSARS‐CoV‐2cellular immunitycross‐reactivityhumoral immunityshort‐term T cell line

Substanzen

Antibodies, ViralAntibodies, NeutralizingImmunoglobulin GViral VaccinesCOVID-19 Vaccines

Autor:innen und Institutionen

  • Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
  • Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah, Riyadh Region, Saudi Arabia.
  • State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Department of Internal Medicine, Section of Infectious Diseases, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
  • Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Guangzhou laboratory, Bio-island, Guangzhou, Guangdong, China.

ORCID-Profile: Bandar Alosaimi, Maaweya Awadalla

Förderung

  • This study was funded by the Research Center at King Fahad Medical City (Grant No. IRF 019-058).
  • King Fahad Medical City

Zitieren

APA

Alosaimi, B., Awadalla, M., Alturaiki, W., Chen, Z., Zhang, Z., Zhu, A., Rebh, F., Alshukairi, A. N., Zhao, J., & Alkadi, H. S. (2025). A 10 Year Long‐Lived Cellular and Humoral MERS‐CoV Immunity Cross‐Recognizing the Wild‐Type and Variants of SARS‐CoV‐2: A Potential One‐Way MERS‐CoV Cross‐Protection Toward a Pan‐Coronavirus Vaccine. Journal of Medical Virology. https://doi.org/10.1002/jmv.70071

Vancouver

Alosaimi B, Awadalla M, Alturaiki W, Chen Z, Zhang Z, Zhu A, et al. A 10 Year Long‐Lived Cellular and Humoral MERS‐CoV Immunity Cross‐Recognizing the Wild‐Type and Variants of SARS‐CoV‐2: A Potential One‐Way MERS‐CoV Cross‐Protection Toward a Pan‐Coronavirus Vaccine. Journal of Medical Virology. 2025. doi:10.1002/jmv.70071

BibTeX
@article{Alosaimi2025,
  author = {Alosaimi, Bandar and Awadalla, Maaweya and Alturaiki, Wael and Chen, Zhao and Zhang, Zhaoyong and Zhu, Airu and Rebh, Fatimah and Alshukairi, Abeer N and Zhao, Jincun and Alkadi, Haitham S},
  title = {A 10 Year Long‐Lived Cellular and Humoral MERS‐CoV Immunity Cross‐Recognizing the Wild‐Type and Variants of SARS‐CoV‐2: A Potential One‐Way MERS‐CoV Cross‐Protection Toward a Pan‐Coronavirus Vaccine},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70071}
}
Kostenlos starten →